Double-blind Randomized Parallel Arm Study of 3 Anti CD20 Monoclonal Antibodies in Patients with Moderate to Severe, Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate Based Therapy. Efficacy Safety & Immunogenicity Results

被引：0
|
作者：
Haridas, Vikram [1 ]
Katta, Rahul [2 ,3 ]
Nalawade, Ajit [4 ]
Kharkar, Sandeep [5 ]
Zhdan, Vyacheslav [6 ]
Garmish, Olena [7 ]
Lopez-Lazaro, Luis [8 ]
Batra, Sonica [9 ]
Kankanwadi, Suresh [10 ]
机构：
[1] Sushruta Multispecial Hosp, Hubballi, Karnataka, India
[2] Katta Hosp, Jaipur, Rajasthan, India
[3] SR Kalla Mem Gen Hosp, Jaipur, Rajasthan, India
[4] Inamdar Multispecialty Hosp, Pune, Maharashtra, India
[5] CARE Hosp, Nagpur, Maharashtra, India
[6] MV Sklifosovskyi Poltava Reg Clin Hosp, Ukrainian Med Stomatol Acad, Higher State Educ Inst Ukraine, Dept Rheumatol, Poltava, Ukraine
[7] NAMSU, SI NS MD Strazhesko Inst Cardiol, Kiev, Ukraine
[8] Dr Reddys Labs SA, Basel, Switzerland
[9] Dr Reddys Labs Ltd, Bachupally, Telangana, India
[10] Dr Reddys Labs EU Ltd, Cambridge, England
来源：
JOURNAL OF RHEUMATOLOGY | 2018年 / 45卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
224
引用
收藏
页码：1052 / 1052
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) & Pharmacodynamics (PD) Results of a Double-blind Randomized Parallel Arm Study Comparing 3 Anti CD20 Monoclonal Antibodies in Moderate to Severe Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate Patients
    Haridas, Vikram
    Katta, Rahul
    Nalawade, Ajit
    Kharkar, Sandeep
    Zhdan, Vyacheslav
    Garmish, Olena
    Lopez-Lazaro, Luis
    Batra, Sonica
    Kankanwadi, Suresh
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 1051 - 1052
  • [2] Results of a phase II, double-blind, randomized study of a nondepleting anti-CD4 monoclonal antibody (Clenoliximab) given in combination with methotrexate (MTX) in patients with moderate to severe rheumatoid arthritis (RA)
    Luggen, ME
    Schechtman, J
    Kivitz, A
    Greenwald, M
    Forstot, J
    Boling, E
    Aldworth, J
    Ingram, M
    Totoritis, M
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 99 - 99
  • [3] Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
    Cohen, Stanley B.
    Genovese, Mark C.
    Choy, Ernest H.
    Perez-Ruiz, Fernando
    Pablos, Jose L.
    Zhang, Nan
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-Severe Rheumatoid Arthritis: Results of a Randomized Double-Blind Study
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [5] COMPARISON OF THE EFFICACY, SAFETY AND IMMUNOGENICITY OF A PROPOSED BIOSIMILAR MSB11456 WITH TOCILIZUMAB REFERENCE PRODUCT IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED DOUBLE-BLIND STUDY
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [6] EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY
    Smolen, J. S.
    Weinblatt, M. E.
    van der Heijde, D.
    Rigby, W. F.
    van Vollenhoven, R.
    Bingham, C. O., III
    Veenhuizen, M.
    Gill, A.
    Zou, H.
    Komocsar, W.
    Berclaz, P. -Y.
    Ortmann, R.
    Lee, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 504 - 504
  • [7] A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate
    Matsuno, Hiroaki
    Tomomitsu, Masato
    Hagino, Atsushi
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [8] A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA).
    Kivitz, Alan J.
    Olech, Ewa
    Borofsky, Michael A.
    Zazueta, Beatriz M.
    Navarro-Sarabia, Federico
    Rowell, Lucy
    Nasmyth-Miller, Clare
    Pope, Janet E.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4170 - 4170
  • [9] Comparison of The Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 With Tocilizumab Reference Product in Moderate-To-Severe Rheumatoid Arthritis: Results of a Randomized Double-Blind Study (Aptura I)
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Pojawa, Malgorzata Socik
    Klama, Kamilla
    Ullmann, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Heidari, Pooneh
    Kudaeva, Fatima
    Truong, Don
    Brzezicki, Jan
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 70 - 70
  • [10] A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Miranda Limon, Juan Manuel
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Gaylis, Norman B.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345